{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T01:21:00Z","timestamp":1778203260296,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2003,4,11]],"date-time":"2003-04-11T00:00:00Z","timestamp":1050019200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2003,6]]},"DOI":"10.1007\/s00520-003-0463-7","type":"journal-article","created":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T03:50:33Z","timestamp":1576122633000},"page":"362-370","source":"Crossref","is-referenced-by-count":22,"title":["Piperacillin-tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison"],"prefix":"10.1007","volume":"11","author":[{"given":"M.","family":"Gorschl\u00fcter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Fixson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Mey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Ziske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Molitor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Horr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Sauerbruch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Marklein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. G. H.","family":"Schmidt-Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Glasmacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2003,4,11]]},"reference":[{"key":"0463_CR1","first-page":"324","volume":"3","author":"Bohme","year":"1998","unstructured":"Bohme A, Shah PM, Stille W, Hoelzer D (1998) Piperacillin\/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study. Eur J Med Res 3:324\u2013330","journal-title":"Eur J Med Res"},{"key":"0463_CR2","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/00006454-199704000-00003","volume":"16","author":"Charnas","year":"1997","unstructured":"Charnas R, Luthi AR, Ruch W (1997) Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children. Pediatr Infect Dis J 16:346\u2013353","journal-title":"Pediatr Infect Dis J"},{"key":"0463_CR3","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1128\/AAC.39.2.445","volume":"39","author":"Cometta","year":"1995","unstructured":"Cometta A, Zinner S, de Bock R, Calandra T, Gaya H, Klastersky J, Langenaeken J, Paesmans M, Viscoli C, Glauser MP (1995) Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother 39:445\u2013452","journal-title":"Antimicrob Agents Chemother"},{"key":"0463_CR4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s002770000247","volume":"80","author":"Cornely","year":"2001","unstructured":"Cornely OA, Bethe U, Salzberger B, Franzen C, Hartmann P, Steinmetz T, Fatkenheuer G, Seifert H, Diehl V, Schrappe M (2001) Randomized controlled monocentric comparison of once daily ceftriaxone with tobramycin and cefotaxime three times daily with tobramycin in neutropenic fever. Ann Hematol 80:103\u2013108","journal-title":"Ann Hematol"},{"key":"0463_CR5","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1086\/322646","volume":"33","author":"Del","year":"2001","unstructured":"Del Favero A, Menichetti F, Martino P, Bucaneve G, Micozzi A, Gentile G, Furno P, Russo D, D'Antonio D, Ricci P, Martino B, Mandelli F (2001) A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis 33:1295\u20131301","journal-title":"Clin Infect Dis"},{"key":"0463_CR6","doi-asserted-by":"crossref","first-page":"584","DOI":"10.7326\/0003-4819-119-7_Part_1-199310010-00006","volume":"119","author":"EORTC-IATCG","year":"1993","unstructured":"EORTC-IATCG (1993) Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Ann Intern Med 119:584\u2013593","journal-title":"Ann Intern Med"},{"key":"0463_CR7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s005200000105","volume":"8","author":"Furno","year":"2000","unstructured":"Furno P, Dionisi MS, Bucaneve G, Menichetti F, Del Favero A (2000) Ceftriaxone versus beta-lactams with antipseudomonal activity for empirical, combined antibiotic therapy in febrile neutropenia: a meta-analysis. Support Care Cancer 8:293\u2013301","journal-title":"Support Care Cancer"},{"key":"0463_CR8","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1046\/j.1439-0507.1999.00518.x","volume":"42","author":"Glasmacher","year":"1999","unstructured":"Glasmacher A, Hahn C, Molitor E, Marklein G, Sauerbruch T, Schmidt-Wolf IG (1999) Itraconazole through concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules. Mycoses 42:591\u2013600","journal-title":"Mycoses"},{"issue":"[Suppl 3","key":"0463_CR9","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1007\/BF01745248","volume":"20","author":"SL Gorbach","year":"1994","unstructured":"Gorbach SL (1994) Piperacillin\/tazobactam in the treatment of polymicrobial infections. Intensive Care Med 20 [Suppl 3]:S27\u2013S34","journal-title":"Intensive Care Med"},{"key":"0463_CR10","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1179\/joc.1997.9.4.267","volume":"9","author":"Hazel","year":"1997","unstructured":"Hazel DL, Graham J, Dickinson JP, Newland AC, Kelsey SM (1997) Piperacillin-tazobactam as empiric monotherapy in febrile neutropenic patients with haematological malignancies. J Chemother 9:267\u2013272","journal-title":"J Chemother"},{"key":"0463_CR11","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s005200050184","volume":"6","author":"Hess","year":"1998","unstructured":"Hess U, Bohme C, Rey K, Senn HJ (1998) Monotherapy with piperacillin\/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients. Support Care Cancer 6:402\u2013409","journal-title":"Support Care Cancer"},{"key":"0463_CR12","doi-asserted-by":"crossref","unstructured":"Higashitani F, Nishida K, Hyodo A, Inoue M (1995) Effects of tazobactam on the frequency of the emergence of resistant strains from Enterobacter cloacae, Citrobacter freundii, and Proteus vulgaris (beta-lactamase derepressed mutants). J Antibiot (Tokyo) 48:1027\u20131033","DOI":"10.7164\/antibiotics.48.1027"},{"key":"0463_CR13","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1086\/339215","volume":"34","author":"Hughes","year":"2002","unstructured":"Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730\u2013751","journal-title":"Clin Infect Dis"},{"key":"0463_CR14","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1128\/AAC.41.10.2177","volume":"41","author":"Kadima","year":"1997","unstructured":"Kadima TA, Weiner JH (1997) Mechanism of suppression of piperacillin resistance in enterobacteria by tazobactam. Antimicrob Agents Chemother 41:2177\u20132183","journal-title":"Antimicrob Agents Chemother"},{"key":"0463_CR15","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1056\/NEJM199907293410502","volume":"341","author":"Kern","year":"1999","unstructured":"Kern WV, Cometta A, de Bock R, Langenaeken J, Paesmans M, Gaya H (1999) Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperatve Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 341:312\u2013318","journal-title":"N Engl J Med"},{"key":"0463_CR16","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000239118","volume":"39","author":"Leoni","year":"1993","unstructured":"Leoni F, Ciolli S, Pascarella A, Fanci R, Caporale R, Rossi FP (1993) Ceftriaxone plus conventional or single-daily dose amikacin versus ceftazidime\/amikacin as empiric therapy in febrile neutropenic patients. Chemotherapy 39:147\u2013152","journal-title":"Chemotherapy"},{"key":"0463_CR17","first-page":"397","volume":"24","author":"Marie","year":"1995","unstructured":"Marie JP, Vekhoff A, Cony-Makhoul P, Fiere D, Guy H, Herbrecht R, Milpied N, Pico JL, Plantier I (1995) Piperacillin\/tazobactam combination+amikacin versus ceftazidime+amikacin in patients with neutropenia and fever. An open multicenter study. Groupe d'etude des Aplasies Febriles (in French). Presse Med 24:397\u2013401","journal-title":"Presse Med"},{"key":"0463_CR18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s005200050233","volume":"7","author":"Marie","year":"1999","unstructured":"Marie JP, Marjanovic Z, Vekhoff A, Bouvet A, Chast F, Levy V, Baudard M, Legrand O, Rio B, Delmer A, Zittoun R (1999) Piperacillin\/tazobactam plus tobramycin versus ceftazidime plus tobramycin as empiric therapy for fever in severely neutropenic patients. Support Care Cancer 7:89\u201394","journal-title":"Support Care Cancer"},{"key":"0463_CR19","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0140-6736(00)04337-3","volume":"357","author":"Moher","year":"2001","unstructured":"Moher D, Schulz KF, Altman DG, Lepage L (2001) The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 357:1191\u20131194","journal-title":"Lancet"},{"key":"0463_CR20","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2165\/00003495-199957050-00017","volume":"57","author":"Perry","year":"1999","unstructured":"Perry CM, Markham A (1999) Piperacillin\/tazobactam: an updated review of its use in the treatment of bacterial infections. Drugs 57:805\u2013843","journal-title":"Drugs"},{"key":"0463_CR21","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000238878","volume":"37","author":"Schmid","year":"1991","unstructured":"Schmid L, Jeschko M, Wilder-Smith C, Schafroth U, Thurlimann B, Pedrazzini A, Senn H (1991) Ceftriaxone and amikacin versus ceftazidime and amikacin in febrile granulocytopenia. Chemotherapy 37:346\u2013352","journal-title":"Chemotherapy"},{"key":"0463_CR22","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1086\/598620","volume":"29","author":"Zinner","year":"1999","unstructured":"Zinner SH (1999) Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 29:490\u2013494","journal-title":"Clin Infect Dis"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-003-0463-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-003-0463-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-003-0463-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T03:50:38Z","timestamp":1576122638000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-003-0463-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,4,11]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,6]]}},"alternative-id":["0463"],"URL":"https:\/\/doi.org\/10.1007\/s00520-003-0463-7","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,4,11]]}}}